Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TechnologyAdvice

Second patient death in Zafgen’s obesity drug trial

Furtherblood clot incident seen after FDA hit study with a clinical hold

- PMLiVE

Why is behaviour change so difficult? By Patrick Ladbury, Communications Manager at the National Social Marketing Centre.

Patrick Ladbury nudges us to overcome the barriers to behaviour change. Read on to find out.

Say Communications

Ablynx appoints Robert Zeldin chief medical officer

He previously servedat Merck & Co, Novartis and the FDA

- PMLiVE

Express Scripts to offer alternative to Turing’s Daraprim

Andpromises to share compounded formulation with other healthcare payers

- PMLiVE

Pfizer’s Xalkori approved for wider use in Europe

Labelupdate gives the lung cancer therapy a new first-line indication

EU flag

Second biosimilar anti-TNF nears EU market

SamsungBioepis' version of Enbrel recommended for approval by the CHMP

Roche - Basel

Roche drops superbug partnership with Polyphor

But adds inflammation research agreement with Proximagen

- PMLiVE

Langland and CAHG take top prizes at Best of Health Awards

Pick up Gold Apples as the IPA awards celebratestheir 20th anniversary

- PMLiVE

Norrie, Dubery and Perkins form Wethepeople

New consultancy aims to 'bring humanity back'

Publicis

Publicis snaps up Langland

Plans to replicate its approach for new global health and wellness agency network

- PMLiVE

Pfizer signs high-level deal with GPCR specialist Heptares

Wide-rangingdeal will involve up to 10 drug targets

- PMLiVE

BMS’ Empliciti approved by FDA for multiple myeloma

Clearedfor use in with Celgene's Revlimid and corticosteroid dexamethasone

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links